Steroid shot may buy time for men with tough prostate cancer

NCT ID NCT07161778

Completed Disease control Sponsor: Barts & The London NHS Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tested a steroid injection called triamcinolone in 55 men with castration resistant prostate cancer, a type that no longer responds to standard hormone therapy. The goal was to see if it could extend the time before chemotherapy is needed, since current steroid treatments only work about 4 months on average. Researchers believe triamcinolone may work differently and avoid resistance seen with other steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: triamcinolone injection
What this could lead to: If it works, this could offer a longer period of disease control before chemotherapy is needed, improving quality of life for older men.
What could go wrong: This is a small, early-phase trial with only 55 participants and no comparison group, so results may not be conclusive. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Raigmore Hospital

Inverness, United Kingdom
Royal Sussex County Hospital

Brighton, United Kingdom
St Bartholomew's Hospital

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.